A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Gastric cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Everest Medicines
- 01 Mar 2023 Planned number of patients changed from 180 to 300.
- 01 Mar 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Dec 2025.
- 17 Nov 2021 New trial record